Association of G/C (rs638405) Polymorphism in [beta]-secretase Gene with Alzheimer's Disease.
Alzheimer's Disease (AD) is the most common cause of dementia that more than 15 million people are suffering from this disease worldwide. This disease is a neurodegenerative disorder and its most important pathological characteristics are [beta]-amyloid plaques and neurofibrillary tangles that are formed through the accumulation of P-amyloid peptides outside neurons and hyperphosphorylated tau protein within neurons, respectively (1,2). [beta]-amyloid peptides are in two forms, 40 or 42 amino acids (3,4). There is a strong association between familial AD and increasing production of 42-amino acid [beta]-amyloid peptide (5,6). Increase in P-amyloid peptides occurs years before the occurrence of AD symptoms; therefore, the increase in [beta]-amyloid peptides will trigger AD pathology (7,8). P-amyloid peptides are produced through endoproteolysis of the Amyloid Precursor Protein (APP) that is a large type-I transmembrane protein (9,10) . Amyloid precursor protein which exists in all cells is cleaved by three proteases including [alpha]-secretase, [beta]-secretase, and [gamma]-secretase.
APP is first cleaved by [alpha]- or [beta]-secretase and then the membrane-bound remaining is further cleaved by [gamma]-secretase. [beta]-secretase is a protease that acts in place of amino acid, aspartic acid and produces [beta]-amyloid peptide and the C99 fragment, the 99 amino acids from the C-terminal of the amyloid precursor protein. Next, y-secretase cleaves amyloid precursor protein and produces p-amyloid peptides with different sizes, [alpha]-secretase with the effect on the amyloid precursor protein produces C83 fragment. Because the a-secretase is not able to produce [beta]-amyloid peptides longer, thus does not produce beta-amyloid plaques. But [beta]-secretase and [gamma]-secretase are able to produce P-amyloid peptides. Therefore, APP cleavage by [beta]-secretase and then by [gamma]-secretase is the very well known cause of AD by production and accumulation of [beta]-amyloid plaques in the brain.
In this pathway, P-secretase is a key enzyme and its activation or inactivation is essential for creation and the treatment of AD (7). [beta]-secretase has two isoforms including p-Secretase Enzyme in AD I (BACEl) and P-Secretase Enzyme in AD 2 (BACE2). These two enzymes are similar; however, BACEI is more important and is a key enzyme in the production of P-amy-loid peptides and formation of p-amyloid plaques. The BACEI is a membrane-bound enzyme from pepsin family and can cleave peptide bind of aspartic and glutamic acid of amyloid precursor protein (7). Several factors have been reported to affect the BACEI activity and gene expression; for instance, hypoxia (11), heat shock (12) and cytokines (13,14).
In addition, Single Nucleotide Polymorphism (SNP) affects BACEI activity and gene expression. The BACEI gene is located on chromosome 11 (11q23.3) and it seems that genetic variation in this gene can increase the risk of AD. SNP is very important for making phenotypes. Although there are 23 genetic locations on BACEI gene for making polymorphism, few of these sites can increase the risk of AD (15). Many studies have been done on this subject. For example, Todd et al conducted a study on northern Irish population and showed that 11 genetic locations in BACEI gene are not related with risk of AD (l6). However, polymorphism of G/C (rs638405) within exon 5 of the BACEI gene is especially important. Several case-control studies stated that it is possible that G allele of the BACEI gene increases the risk of AD (17-20), but other studies showed it is not related to increased risk of AD (21-24). In addition, several meta-analyses have been conducted on this polymorphism. For example, a meta-analysis of 9 case-control studies shows that there is not a significant relationship between polymorphism in exon 5 of BACEI gene and risk of AD (25). However, a study that has been done by Jo et al revealed that there is a weak relationship between this polymorphism and risk of AD in Asian population (23).
In addition, in other meta-analysis Wang et al proved that GG genotype and G allele of polymorphism of G/C (rs638405) within exon 5 of the BACEI gene possibly increase the risk of AD (26). However, in another study, Yu et al stated that polymorphism of G/C (rs638405) of the BACEI gene might decrease the risk of AD in Asian and APOE4 positive patients (15). Therefore, polymorphism of G/C (rs638405) within exon 5 of the BACEI gene can be related with the increased risk of AD (20). Thus, due to the growing prevalence of AD and the important role of some single nucleotide polymorphisms in AD risk, this study was carried out to evaluate the association between polymorphism of BACEI gene, G/C (rs638405), and sporadic AD in population of Khuzestan, Isfahan and Fars provinces in Iran.
Materials and Methods
A total of AD patients and controls were recruited from outpatient clinics of several medical centers. Using statistical formulas, the sample size for this study was about 300 in each group, but due to the rare nature of Alzheimer's samples, relevant information was collected from 6 August, 2013 to 26 November, 2013 from three provinces of Khuzestan, Isfahan and Fars. Therefore, the number of samples for comparing this ratio in each group was about 80 people. The subjects in this project consisted of 162 individuals living in Khuzestan, Isfahan and Fars provinces in Iran. The AD group consisted of 89 patients (mean age= 72.40 years, SD=10.251, range=51-94) and the second group consisted of 73 healthy subjects as the control group (mean age=70.78 years, SD=6.112, range=65-91).
For the diagnosis of AD patients, medical examination, DSM-IV criteria and neurological tests including Computed Tomography (CT) or brain magnetic resonance imaging (MR1) and cognitive function tests, including Mini-Mental State Examination (MMSE) were used by an expert neurologist. Each control subject was identified by medical interview, medical history and cognitive function tests, including mini-mental state examination (MMSE). The control subjects had a MMSE score of >26. Control group was selected from individuals monitored by the neurologist from several medical centers in Ahvaz city. The informed consent was taken from the control group and due to the patient's condition in AD group and lack of optimal consciousness in advanced stages, their guardians submitted the consent form. The ethics committee of Ahvaz Jundishapur University of Medical Sciences approved the procedure.
Isolation of DNA and genotyping
Genomic DNA was isolated from whole blood samples with a standard procedure by using the QIAamp blood kit (QIAGEN, Hilden, Germany). Blood samples (2.0 ml) were collected in blood tubes, where they were stored or transported. For DNA isolation, the blood was transferred to processing tubes (filled with cell lysis buffer), and the solution was mixed with lyse red and white blood cells. Cell nuclei were pelleted by centrifugation, washed, and resuspended in digestion buffer. Protein contaminants were removed by incubation with a protease. DNA was precipitated in isopropanol, washed in 70% ethanol, dried, and resuspended in resuspension buffer.
Genotyping of BACEI gene G/C (rs63840S) polymorphism
Genotypes were determined by the PCR-restriction fragment length polymorphism (PCR-RFLP) technique. For G/C SNP of BACEI gene, the forward primer was 5'-CTGATCTTATTGCTTGGTCCTTGG G-3' and the reverse primer was 5'-CTTATGTTCCCA GGCTCTCCCTTG-3' (20). PCR was performed using 1 fig of genomic DNA in 7 [micro]l sterile D.W, 13 [micro]/ master mix PCR (Taq DNA Polymerase 2x Master Mix RED; Ampliqon, Denmark) and 0.2 [micro]M of each primer (27). The PCR cycling conditions were 5 min at 95 [degrees]C followed by 30 cycles of 30 s at 95 V., 30 5 at 59 [degrees]C and 45 s at 72 [degrees]C, with a final step at 72 [degrees]C for 5 min to allow for the complete extension of all PCR fragments. To determine the genotypes of G/C (rs638405) polymorphism of BACE1 gene, PCR product was digested with the Bell restriction enzyme (Thermo Scientific or Fermentas, Germany) at 55 [degrees]C for 2 hr. The productions of enzymatic digestion were investigated by 2% agarose gel stained with safe stain under ultraviolet light.
The data were analyzed by using SPSS program for windows version 18.0. Allelic frequencies were estimated by the allele counting method. To compare genotypes and alleles frequencies between AD patients and controls Chi-Square ([chi square]) test was used. For obtaining OR, Chi-Square ([chi square]) test was applied. The statistical significance was supposed at p<0.05.
Genotypes and alleles frequencies in BACEl gene polymorphism of G/C (rs638405)
The size of PCR products was 249 bp. In the case of BACEl, G allele generated two fragments of 160 and 89 bp, and in the case of C allele an uncut fragment of 249 bp was detected (Figure 1) (15). Next, the possible risk of AD associated with BACEl gene polymorphism of G/C (rs638405) was analyzed. For this aim, the demographic characteristics of the study subjects including 89 AD patients and 73 healthy controls were summarized. Frequency of men and women, the mean age and MMSE score for all subjects are shown in table 1. Chi-Square test and Mann-Whitney test were used to determine the relationship between sex and age with the AD, respectively. Unexpectedly, no statistically significant differences were found between sex and age with the AD and control populations (p>0.05). This means that sex and age may not be a confounding factor for AD. The results of allele and genotypes frequencies analysis in AD patients and control group are presented in table 2. Moreover, results of allele and genotypes frequencies analysis in AD patients and control group, when AD and control groups were stratified by sex, are shown completely in table 3. The findings of the study revealed that there was no significant difference in alleles and genotypes frequencies between AD patients and controls. However, when the AD patients and controls were stratified by sex, a weak difference was observed in the frequency of CC genotype between AD patients and controls in women ([chi square]=3.333, df=l, p=0.068). In addition, there was a significant difference in C allele frequency between AD patients and controls in women ([chi square]=4.645, df=l, p=0.031)(Table 3).
AD is the most common cause of dementia and this disease is a neurodegenerative disorder. Its most important pathological characteristics are p-amyloid plaques and neurofibrillary tangles that are formed through the accumulation of p-amyloid peptides outside neurons and hyperphosphorylated tau protein within neurons, respectively (1,2). Currently, examining the effective factors in the risk of developing AD can be useful for diagnosis and treatment of this problem (28). Researchers have shown that both genetic and environmental factors affect the risk of AD (29). Despite many studies that have been done in the field of diagnosis and treatment of AD, the cause of the disease has remained unknown (28). However, as mentioned before, genetic factors may affect the risk of developing AD.
One of these genetic factors is the SNP in genes related to proteins that are involved in the development of AD. For example, in one of our studies, it was found that polymorphism of G/A (rs34011) within FGF1 gene and AA genotype and A allele may be associated with the risk of developing AD in people of Khuzestan, Isfahan and Fars provinces in Iran (30). Like the polymorphisms related to APOE, CYP46A1 and BDNF genes have been studied in different countries and the results indicated that these polymorphisms can be associated with the risk of developing AD (31-33). In addition, the SNP related to BACE1 gene can be considered as an important genetic risk factor for developing AD (23-34).
The BACE1 is expressed in human pancreatic tissue and neurons in the brain at high levels (7). However, the pancreatic BACE1 is in an inactive isoform and does not produce p-amyloid plaques (35,36). The BACE1 is a key enzyme in the production of P-amyloid peptides; therefore, activation and inactivation of the BACE1 is necessary for generation and remedy of p-amyloid plaques and any changes in this enzyme can be related to AD. The SNP affects BACE1 gene activity and expression and can be related to AD. The BACE1 gene is placed on chromosome 11 (1 lq23.3) (37). Several studies have been done on BACE1 gene polymorphisms in AD patients, suggesting that G/C (rs638405) polymorphism within exon 5 of the BACE1 gene is an important risk factor for causing and developing AD. For example, in one study, Kan et al reported that G/C (rs638405) polymorphism of BACE1 gene and GG genotype are important genetic risk factors for developing AD in China (20). In another study, Gold et al evaluated polymorphism of G/C (rs638405) BACE1 gene in association with APO[epsilon]4 allele and indicated a synergetic effect between the G-allele and APO[epsilon]4 allele on the risk of developing AD in Switzerland (37). However, Shi et al revealed that the C-allele was the risk factor for developing AD (38). However, Liu et al stated that G/C (rs638405) polymorphism of BACE1 gene is not related with increased levels of [beta]-amyloid plaques in brain tissue (22). The distributions of alleles or genotype frequencies of G/C (rs638405) in different populations suggest the ethnical variability in the populations.
In this study, G/C (rs638405) polymorphism of BACEJ gene was analyzed for the first time in Khuzestan, Isfahan and Fars provinces of Iran. In agreement with other studies (22), our data showed that there was no significant difference in alleles and genotype frequencies between AD patients and controls. But our results, unlike a study that Nowotny el al conducted, evaluated polymorphism of G/C (rs638405) BACEJ gene in association with APOs4 allele and they concluded that there was no significant difference in alleles and genotypes frequencies between AD patients and controls (19). In addition, Clarimon et al revealed a relationship between GG genotype of G/C (rs638405) gene in relation with APOs4 allele and AD (18), though our data stated that the G/C (rs638405) polymorphism of BACE1 gene might not be related with sporadic AD in Khuzestan, Isfahan and Fars provinces in Iran. However, when the AD patients and controls were stratified by sex, our results revealed that there is a weak difference in the frequency of CC genotype between patients and controls in women. Also, Shi et a! in agreement with our study stated that CC genotype of polymorphism of BACE1 gene is associated with sporadic AD in Chinese Hans (38), although Kan et al indicated that there was a synergetic association between G-allele of G/C (rs638405) polymorphism and apo-lipoprotein E allele 4 with risk of Late-Onset AD in Chinese (20). A possible and more likely reason may be that the smaller number of male subsets than female subsets in AD natients is responsible for the lack of association between GG-homozygotes genotypes and G allele status with increases in the risk of AD in male subsets. Increasing the sample size to make sure whether the G/C (rs638405) polymorphism of BACE 1 gene is associated with the AD risk in Khuzestan, Isfahan and Fars provinces in Iran seems to be a necessary strategy to apply.
In conclusion, the results of this study suggest that the G/C (rs638405) polymorphism of BACE1 gene might not be related with sporadic AD in Khuzestan, Isfahan and Fars provinces in Iran, and the BACE1 gene CC genotype frequency or C allele frequency might be a genetic risk factor for developing AD in Khuzestan, Isfahan and Fars provinces in Iran. Further studies in other populations with different ethnicities are needed to clarify the relationship of these polymorphisms with gene expression in AD patients. Polymorphism G/C (rs638405) in the BACE1 gene is not the only polymorphism in this gene; other polymorphisms in BACE1 gene may also increase the risk for AD. Synergistic interaction may exist between the polymorphism of the BACE1 gene and other genes involved in the AD, such as the ApoE and CYP46A1 genes (27). Therefore, further studies investigating the effects of the BACEl gene polymorphism are needed in the future to confirm the substantial role of this gene in the pathogenesis of AD.
This work was financially supported by grant CMRC-124 from vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
(1.) De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000;113:1857-1870.
(2.) Zhang X, Li Y, Xu H, Zhang YW. The [gamma]-secretase complex: from structure to function. Front Cell Neurosci 2013;8:427.
(3.) Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Alzheimer Dis Assoc Disord 1988;2(2): 134.
(4.) De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem 2012;65:329-352.
(5.) Younkin SG. The role of A[gamma]42 in Alzheimer's disease. J Physiol Paris 1998;92(3-4):289-292.
(6.) Vassar R. beta-Secretase, APP and Abeta in Alzheimer's disease. Subcell Biochem 2005;38:79-103.
(7.) Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004;23(l-2): 105-114.
(8.) Tran L, Ha-Duong T. Exploring the Alzheimer amyloid-P peptide conformational ensemble: A review of molecular dynamics approaches. Peptides 2015;69:86-91.
(9.) Vassar R, Citron M. Ap-generating enzymes: recent advances in [beta]-and [gamma]-secretase research. Neuron 2000; 27(3):419-422.
(10.) Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiolog Rev 2001;81(2):741-766.
(11.) Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, et al. Hypoxia-inducible factor 1 alpha (HIF-lalpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007;282(15): 10873-10880.
(12.) Lahiri DK, Maloney B, Ge YW. BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation. J Mol Neurosci 2006;28(2): 193-210.
(13.) Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-KB in neurons and glia upon exposure to [beta]-amyloid peptides. J Neurosci Res 2007;85(6): 1194-1204.
(14.) Cho HJ, Kim SK, Jin SM, Hwang EM, Kim YS, Huh K, et al. IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT 1 to BACE1 promoter in astrocytes. Glia 2007;55(3):253-262.
(15.) Yu M, Liu Y, Shen J, Lv D, Zhang J. Meta-analysis of BACE1 gene rs638405 polymorphism and the risk of Alzheimer's disease in Caucasion and Asian population. Neurosci lett 2016;616:189-196.
(16.) Todd S, McKnight AJ, Liu WW, Carson R, Heggarty S, McGuinness B, et al. BACE1 polymorphisms do not influence platelet membrane p-secretase activity or genetic susceptibility for Alzheimer's disease in the northern Irish population. Neuromolecular Med 2008;10(4):368-376.
(17.) Cai L, Tang G, Chen L, Zhang B, Jiang S, Ren D. Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients. Neuroreport 2005; 16(9): 1023-1026.
(18.) Clarimon J, Bertranpetit J, Calafell F, Boada M, Tarraga L, Comas D. Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1. J Neurol 2003;250(8):956-961.
(19.) Nowotny P, Kwon JM, Chakraverty S, Nowotny V, Morris JC, Goate AM. Association studies using novel polymorphisms in BACE1 and BACE2. Neuroreport 2001;12(9):1799-1802.
(20.) Kan R, Wang B, Zhang C, Jin F, Yang Z, Ji S, et al. Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer's disease in Chinese. J Mol Neurosci 2005;25(2): 127-131.
(21.) Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko D, et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging 2011;32(3):556. el3-e23.
(22.) Liu HC, Leu SJ, Chang JG, Sung SM, Hsu WC, Lee LS, et al. The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer's disease. Brain Res 2003;961(1):88-91.
(23.) Jo SA, Ahn K, Kim E, Kim HS, Jo I, Kim DK, et al. Association of BACE 1 gene polymorphism with Alzheimer's disease in Asian populations: meta-analysis including Korean samples. Dement Geriatr Cogn Disord 2008;25(2): 165-169.
(24.) Murphy T, Yip A, Brayne C, Easton D, Evans JG, Xuereb J, et al. The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. Neuroreport 2001;12(3):631-634.
(25.) Llorca J, Rodriguez-Rodriguez E, Dierssen-Sotos T, Delgado-Rodriguez M, Berciano J, Combarros O. Metaanalysis of genetic variability in the beta-amyloid production, aggregation and degradation metabolic pathways and the risk of Alzheimer's disease. Acta Neurol Scand2008;l 17(1): 1-14.
(26.) Wang M, Yang J, Su J. Relationship between the polymorphism in exon 5 of BACE1 gene and Alzheimer's disease. Aging Clin Exp Res 2017;29(2): 105-113.
(27.) Mousavidehmordi R, Babaahmadi H, Shalbafan B, Mohammadzadeh G, Afsharmanesh M, Kheirollah A. Polymorphism of CYP46A1 gene and Alzheimer's disease in the Iranian population. Shiraz E-Med J 2016; 17(9):e41218.
(28.) Yamagata H, Chen Y, Akatsu H, Kamino K, Ito JI, Yokoyama S, et al. Promoter polymorphism in fibroblast growth factor 1 gene increases risk of definite Alzheimer's disease. Biochem Biophys Res Commun 2004;321 (2):320-323.
(29.) Kawas C, Katzman R. Epidemiology of dementia and Alzheimer disease. Alzheimer Disease 1999;2:95-116.
(30.) Chashmpoosh M, Babaahmadi H, Mosavidehmordi R, Mohammadi A, Kheirollah A. The Association between G/A (rs34011) Polymorphism of the FGF1 Gene and Alzheimer's Disease. J Mazandaran Univ Med Sci 2016;25(134):89-97.
(31.) Raygani AV, Zahrai M, Raygani AV, Doosti M, Javadi E, Rezaei M, et al. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neurosci Lett 2005;375(1): 1-6.
(32.) He XM, Zhang ZX, Zhang JW, Zhou YT, Wu CB, Tang MN, et al. An intronic CYP46A1 polymorphism is associated with Alzheimer disease in a Chinese Han population. J Mol Neurosci 2012;47(3):514-518.
(33.) Bian JT, Zhang JW, Zhang ZX, Zhao HL. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese. Neurosci Lett 2005;387(1): 11-16.
(34.) Tsai A, Huang CC, Yang AC, Liu ME, Tu PC, Hong CJ, et al. Association of BACE1 gene polymorphism with cerebellar volume but not cognitive function in normal individuals. Dement Geriatr Cogn Dis Extra 2012;2(1): 632-637.
(35.) Bodendorf U, Fischer F, Bodian D, Multhaup G, Paganetti P. A splice variant of [beta]-secretase deficient in the amyloidogenic processing of the amyloid precursor protein. J Biological Chem 2001 ;276( 15): 12019-12023.
(36.) Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402(676I):537-540.
(37.) Gold G, Blouin JL, Herrmann FR, Michon A, Mulligan R, Duriaux Sail G, et al. Specific BACE1 genotypes provide additional risk for late-onset alzheimer disease in APOE epsilon 4 carriers. Am J Med Genet B Neuropsychiatr Genet 2003; 119B(1):44-47.
(38.) Shi J, Zhang S, Tang M, Liu X, Li T, Wang Y, et al. The 1239G/C polymorphism in exon 5 of BACE1 gene may be associated with sporadic Alzheimer's disease in Chinese Hans. Am J Med Genet B Neuropsychiatr Genet 2004;124B(l):54-57.
Mostafa Chashmpoosh (1), Hossein Babaahmadi (1), Rouhollah Mousavidehmordi (1), Bita Shalbafan (2), Asma Mohammadi (1), and Alireza Kheirollah (1*)
(1.) Department of Biochemistry, Faculty of Medical, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
(2.) Department of Neurology, Faculty of Medical, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
(*) Corresponding author: Alireza Kheirollah, Ph.D., Department of Biochemistry, Cellular & Molecular Research Center, Ahuaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Tel: +98 9167505075
Fax: +98 613 373 8632
Received: 22 Mar 2017
Accepted: 8 Jul 2017
Table 1. Frequency of sex distribution, the mean age, and MMSE score in AD and controls [polymorphism of G/C (rs638405) BACEl gene] Gender Subjects Number Male Female Mean age MMSE AD patients 89 34 55 72,40 years Variable Controls 73 32 41 70.78 years 26< MMSE Total 162 66 96 Table 2. The distribution of the BACEl genotypes and alleles frequencies in AD patients and control subjects Total Genotype/allele p-value OR (95%CI) Patients Controls GG 4(2.5%) 2(1.2%) 0.414 Reference GC 59(36.4%) 50(30.8%) 0.389 1.03(0.64-1.68) CC 26(16.1%) 21(13.0%) 0.466 0.98(0.52-1.88) G 67(37.6%) 54(37.0%) 0.237 Reference C 111(62.4%) 92(63.0%) 0.182 1.01(0.67-1.53) Table 3. The distribution of the BACEl genotypes and alleles frequencies in AD patients and control subjects, stratified by sex in male and female subsets Male Genotype/allele p-value OR(95%CI) Patients Controls GG 3(4.6%) 1(1.5%) 0.317 Reference GC 25(37.5%) 20(30.3%) 0.456 0.58(0.4-1.81) CC 6(9 1%) 11(16.6%) 0.225 1.95(0.66-5 72) G 31(45.6%) 22(34.4%) 0.216 Reference C 37(54,4%) 42(65.6%) 0.574 1.21(0,63-2.31) Female Genotype/allele p-value OR(95%CI) Patients Controls GG 1(1.05%) 1(1.05%) 1.000 Reference GC 34(35.4%) 30.(31.2%) 0.617 1.18(0.63-2.23) CC 20(20.9%) 10(10.4%) 0.068 0.67(0.29-1.57) G 36(32.7%) 32(39.0%) 0.628 Reference C 74(67.3%) 50(61.0%) 0.031 0.55(0.32-0.95)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Chashmpoosh, Mostafa; Babaahmadi, Hossein; Mousavidehmordi, Rouhollah; Shalbafan, Bita; Mohammadi, A|
|Publication:||Avicenna Journal of Medical Biotechnology (AJMB)|
|Date:||Oct 1, 2018|
|Previous Article:||Exploring Potential Biomarkers Underlying Pathogenesis of Alzheimer's Disease by Differential Co-expression Analysis.|
|Next Article:||Interaction Effect of Rsal and BamHI Polymorphisms of TGF[alpha], BMP2 and BMP4 on the Occurrence of Non-Syndromic Cleft Lip and Palate in Iranian...|